More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, most of which are asymptomatic. 1 FDA CLIA-waived tests broaden access to ...
Roche has received 510(k) clearance with a Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver from the US Food and Drug Administration (FDA) for its cobas liat sexually transmitted ...
The cobas is classified as a four-in-one molecular test that can identify SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus from a single nasopharyngeal or anterior nasal swab ...
Roche Holdings AGRHHBY recently launched CE-IVD - the cobas MRSA/SA nucleic acid test. The test will be used on the cobas Liat System for the qualitative detection and differentiation of ...
Roche ($RHHBY) has launched the Laboratory-in-a-tube (Liat) technology it acquired when it bought iQuum in April for $275 million up front and up to $175 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results